Table 3. The changes of symptom scores and VUDS parameters after the first and repeat external urethral sphincter onabotulinumtoxinA injection therapy within dysfunctional voiding (DV) and detrusor underactivity (DU) patients.
DV (N = 7) |
DU (N = 12) |
|||||
---|---|---|---|---|---|---|
Changes after the 1st injection | Changes after repeat injection | P value# | Changes after the 1st Injection | Changes after repeat injection | P value# | |
IPSS-V | −4.0 ± 5.5 | −3.4 ± 5.4 | 0.848 | −1.0 ± 4.0 | −6.3 ± 7.0* | 0.035 |
IPSS-S | −2.3 ± 3.9 | −3.4 ± 3.3* | 0.563 | −2.1 ± 3.8 | −4.5 ± 5.7* | 0.250 |
IPSS-T | −6.3 ± 6.7* | −6.9 ± 3.5* | 0.846 | −3.0 ± 5.0 | −10.7 ± 10.8* | 0.051 |
QoL-I | −1.0 ± 2.2 | −2.0 ± 1.5* | 0.337 | −1.8 ± 1.8* | −3.1 ± 2.2* | 0.144 |
PPBC | −0.9 ± 2.7 | −1.7 ± 1.8* | 0.502 | −0.9 ± 1.6 | −1.8 ± 1.7* | 0.202 |
CBC (mL) | 60.6 ± 105.5 | 143.3 ± 143.0* | 0.242 | 32.1 ± 72.8 | 77.2 ± 148.5 | 0.381 |
Pdet (cmH2O) | −8.1 ± 14.7 | −13.4 ± 21.1 | 0.597 | 5.2 ± 10.7 | 3.8 ± 10.0 | 0.719 |
Qmax (mL/s) | 1.3 ± 5.2 | 2.6 ± 6.0 | 0.676 | −0.6 ± 3.8 | 5.4 ± 5.5* | 0.008 |
Vol. (mL) | 17.9 ± 64.7 | 29.7 ± 55.8 | 0.720 | −10.3 ± 94.5 | 57.5 ± 150.5 | 0.206 |
PVR (mL) | 29.1 ± 104.2 | 21.3 ± 124.7 | 0.900 | −1.3 ± 174.4 | −70.9 ± 179.3 | 0.367 |
VE (%) | −7.7 ± 25.8 | −1.9 ± 31.8 | 0.715 | −0.2 ± 17.2 | 19.5 ± 37.1 | 0.113 |
#p value between the changes of the parameters after the 1st and repeat injections.
*p value <0.05 versus baseline (or before the injection therapy).
IPSS, International Prostate Symptom Score; IPSS-V, IPSS voiding subscore; IPSS-S: IPSS storage subscore; IPSS-T, total IPSS score; PPBC, Patient Perception of Bladder Condition score; QoL-I, quality of life index; CBC, cystometric bladder capacity; Pdet, detrusor voiding pressure; Qmax, maximal urinary flow rate; Vol., voided volume; PVR, post-void residual; VE, voiding efficiency.
Data are expressed as mean ± standard deviation.